Ibrance (Palbociclib) Patent Expiration, LOE Window & CMS Spending

Ibrance (Palbociclib) by Pfizer: FDA Orange Book core substance LOE 2034-08-08, 0 AB generics, $2.30B 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN207103 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-08-08
Last Listed Patent or Exclusivity Date2034-08-08
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.30B
2024 Medicare Part D Spend$2.04B
2024 Medicaid Spend$269.8M
Reported Wholesale Price Change (CA SB 17)18 WAC filings (max 22.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.